First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-08-09
Target enrollment:
Participant gender:
Summary
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability,
pharmacokinetics (PK), and immunogenicity of GSK4381562 in participants with select
loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard
treatment options have been exhausted